Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $920K invested in Loncar China BioPharma ETF in 2021 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 1
43% less funds holding
Funds holding: 7 → 4 (-3)
57% less capital invested
Capital invested by funds: $2.13M → $920K (-$1.22M)
67% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
+$48.1K |
| 2 |
Morgan Stanley
New York
|
+$7.01K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$3.73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$761K |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$346K |
| 3 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
-$326K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$23K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Jane Street
New York
| $773K | -$761K | -20,410 | -49% |
|
|
2
Morgan Stanley
New York
| $81K | +$7.01K | +188 | +9% |
|
|
3
UBS Group
Zurich,
Switzerland
| $62K | +$48.1K | +1,291 | +331% |
|
|
4
Royal Bank of Canada
Toronto,
Ontario, Canada
| $4K | +$3.73K | +100 | New |
|
|
5
Citadel Advisors
Miami,
Florida
| – | -$346K | -10,621 | Closed |
|
|
FEM
6
Fulcrum Equity Management
Plano,
Texas
| – | -$326K | -10,023 | Closed |
|
|
7
Osaic Holdings
Scottsdale,
Arizona
| – | -$23K | -719 | Closed |
|
CHNA Hedge Fund Activity: Q1 2021 in Review
4 of the 5,696 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q1 2021, worth a combined $920K — down 57% from $2.13M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of CHNA and 1 opened new positions — a net loss of 2 holders — while 1 trimmed existing stakes and 2 added.
The largest buyer was UBS Group, adding an estimated $48.1K. The largest seller was Jane Street, cutting an estimated $761K.
- 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q1 2021, down from 7 in Q4 2020.
- Funds reported $920K of Loncar China BioPharma ETF stock for Q1 2021, down 57% quarter-over-quarter.
- 1 fund opened new Loncar China BioPharma ETF positions in Q1 2021 and 3 closed out, a net change of -2 holders.
- The largest Loncar China BioPharma ETF buyer in Q1 2021 was UBS Group, an estimated $48.1K added.
- The largest Loncar China BioPharma ETF seller in Q1 2021 was Jane Street, an estimated $761K sold.
Based on aggregated 13F filings for Q1 2021.